# Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome

> **NCT04732507** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **University of Arizona** · enrollment: 300 (estimated)

## Conditions studied

- Myofascial Pain
- Myofascial Trigger Point Pain

## Interventions

- **COMBINATION_PRODUCT:** 1% plain lidocaine and 0.25% plain bupivacaine

## Key facts

- **NCT ID:** NCT04732507
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2021-04-20
- **Primary completion:** 2026-12-09
- **Final completion:** 2026-12-09
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04732507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04732507, "Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04732507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*